{"id":"eltrombopag-combining-rituximab","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombosis"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Eltrombopag is a thrombopoietin receptor agonist that stimulates megakaryocyte maturation and platelet production. Rituximab is a CD20-targeting monoclonal antibody that depletes B cells, reducing autoimmune platelet destruction. The combination addresses both platelet supply and immune-mediated destruction in ITP.","oneSentence":"Eltrombopag and rituximab together work to increase platelet production while depleting B cells to treat immune thrombocytopenia.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:45:19.724Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Immune thrombocytopenia (ITP), refractory or relapsed"}]},"trialDetails":[{"nctId":"NCT05718856","phase":"PHASE4","title":"TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-02-23","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":166},{"nctId":"NCT04518475","phase":"PHASE4","title":"Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2020-08-10","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":224}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TPO-R agonist & anti-CD20 antibody"],"phase":"marketed","status":"active","brandName":"eltrombopag combining rituximab","genericName":"eltrombopag combining rituximab","companyName":"Institute of Hematology & Blood Diseases Hospital, China","companyId":"institute-of-hematology-blood-diseases-hospital-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eltrombopag and rituximab together work to increase platelet production while depleting B cells to treat immune thrombocytopenia. Used for Immune thrombocytopenia (ITP), refractory or relapsed.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}